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Abstract
Remodeling of extracellular matrix (ECM) is a critical step in peripheral nerve regeneration. In fact, in human neuropathies,
endoneurial ECM enriched in fibrin and vitronectin associates with poor regeneration and worse clinical prognosis.
Accordingly in animal models, modification of the fibrinolytic complex activity has profound effects on nerve regeneration:
high fibrinolytic activity and low levels of fibrin correlate with better nerve regeneration. The urokinase plasminogen
receptor (uPAR) is a major component of the fibrinolytic complex, and binding to urokinase plasminogen activator (uPA)
promotes fibrinolysis and cell movement. uPAR is expressed in peripheral nerves, however, little is known on its potential
function on nerve development and regeneration. Thus, we investigated uPAR null mice and observed that uPAR is
dispensable for nerve development, whereas, loss of uPAR affects nerve regeneration. uPAR null mice showed reduced
nerve repair after sciatic nerve crush. This was a consequence of reduced fibrinolytic activity and increased deposition of
endoneurial fibrin and vitronectin. Exogenous fibrinolysis in uPAR null mice rescued nerve repair after sciatic nerve crush.
Finally, we measured the fibrinolytic activity in sural nerve biopsies from patients with peripheral neuropathies. We showed
that neuropathies with defective regeneration had reduced fibrinolytic activity. On the contrary, neuropathies with signs of
active regeneration displayed higher fibrinolytic activity. Overall, our results suggest that enforced fibrinolysis may facilitate
regeneration and outcome of peripheral neuropathies.
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Introduction
Nerve regeneration is a critical step in the outcome of peripheral
neuropathies. It depends on a combination of signals that control
Schwann cell-axon interaction, ensheathment and remyelination.
Incomplete regeneration contributes to clinical severity [1].
Extracellular matrix (ECM) components and their receptors
play a major role in nerve regeneration [2,3,4]. Indeed, we
recently reported that endoneurial ECM composition is
instructive on nerve regeneration and neuropathy outcome [5].
Nerves enriched with fibrin and vitronectin display insufficient
regeneration and poor clinical outcome. Conversely, nerves
devoid of fibrin and vitronectin present abundant signs of
regeneration and better clinical outcome [5]. Whether the
abnormal ECM composition of non-regenerating human nerves
is the consequence of impaired fibrinolysis is not known. If
fibrinolysis plays an active role for nerve regeneration,
modulating fibrinolysis may represent a therapeutic intervention
to favor nerve repair.
Studies in rodents showed that fibrinolytic rearrangement of
the ECM influences peripheral nerve regeneration. Mice
lacking fibrinolytic molecules such as tissue (tPA) and urokinase
plasminogen activator (uPA), or plasminogen (plg) show
impaired nerve regeneration after damage [6]. Among
molecules of the fibrinolytic complex, there is emerging interest
in the role of uPA receptor (uPAR), as it is involved either in
ECM proteolysis or inflammatory cell migration and adhesion
[7,8]. In peripheral nerves, uPAR is expressed in sensory
neurons and Schwann cells [9], and this expression is
m o d u l a t e da f t e rn e r v ed a m a g e[ 1 0 ] .H o w e v e r ,t h er o l eo f
uPAR in peripheral nerve function and regeneration has never
been investigated.
Here we report that uPAR participates in nerve repair and the
fibrinolytic complex activity parallels nerve regeneration in human
neuropathies.
Materials and Methods
Ethics Statement
All the experiments were performed in 2-months-old mice and
approved by the Italian regulations and San Raffaele Institutional
Animal Care and Use Committee (IACUC 487).
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32059For humans samples, written informed consent was received
and accepted from all patients, and the study approved by the San
Raffaele Ethical Committee.
Mice
uPAR2/2 mice, previously described [11], were maintained in
congenic C57BL/6 strain.
Neurophysiology
Ten uPAR null mice and 10 control littermates (2 months old)
were analyzed for sciatic nerve conduction velocity (NCV) and
compound motor action potential (cMAP) in intact nerves, or 45
days post crush as reported [12]. Mice were anesthetized with
avertin and placed under a heating lamp to avoid hypothermia.
Sciatic NCVs were obtained by stimulating the nerve with steel
monopolar needle electrodes. A pair of stimulating electrodes was
inserted subcutaneously near the nerve at the ankle. A second pair
of electrodes was placed at the sciatic notch, to obtain two distinct
sites of stimulation, proximal and distal along the nerve. The
muscular response to the electrical nerve stimulation (cMAP) was
recorded with a pair of needle electrodes; the active electrode was
inserted in muscles in the middle of the paw, while the reference
was placed in the skin between the first and second digit.
Histology and morphometry
Histological analysis of sciatic nerves from mice and sural nerves
from human biopsies were performed as described [13]. For
mouse morphometry, digitalized images of fiber cross sections
were obtained from corresponding levels of the sciatic nerve with a
digital camera (Leica DFC300F) using a 1006 objective of light
microscope (Olympus BX51). At least 5 images from 4 different
animals per genotype at each evaluation were acquired
(25610
3 mm
2 of sciatic nerve per each animal). The morphometry
on semithin sections was analyzed with the Leica QWin software
[12]. The ratio between the mean diameter of an axon and the
mean diameter of the fiber including myelin (g-ratio), was
determined on approximately 200 randomly chosen fibers per
animal (3 animals per genotype).
Immunohistochemistry and Western blotting
These methods have been previously described [12]. Antibodies
used for immunohistochemistry/Western blotting included: anti-
calnexin and beta-tubulin TUB2.1 (Sigma); collagen IV, fibro-
nectin, Fibrin, Mac1, Neurofilament-160, laminin-beta1, laminin-
beta2 (Millipore); Laminin-alpha2 (4H8-2; Alexis); laminin-alpha4
(Santa Cruz); MBP (SMI-94R; Covance); vitronectin (BioTrend).
Sciatic nerve crush
Adult mice were anesthetized with avertin (trichloroethanol,
0.4 mg/gr of body weight and crush injury performed as described
[14]. After skin incision, the sciatic nerve was exposed and crushed
distal to the sciatic notch for 20 seconds with fine forceps
previously cooled in dry ice. To identify the site of injury, forceps
were previously dropped into vital carbon. The nerve was replaced
under the muscle and the incision sutured. All the experiments
have been performed on the distal portion of the crushed nerve.
Mouse DRG cocultures
Mouse DRGs and cocultures were established as described [15].
Briefly, mouse DRGs were isolated from E13.5 embryos and
placed in C-media containing MEM, 10% fetal calf serum,
2%glucose, 2 mM glutamine, purchased from Life Science and
50 ng/ml Nerve Growth Factor (NGF, from Serotec) on collagen
coated glass coverslips. The day after the C-media was removed
and replaced for 4–5 days with Neurobasal medium and B27
(vol 1:1, Life Sciences) without serum and supplemented with
NGF, glucose and glutamine as above. Glass coverslips were pre-
coated with PLL (final concentration 0.1 mg/ml) and subsequent-
ly coated with collagen (rat collagen 0.5 mg/ml from Trevigen).
Myelination was induced by treatment for 14 days with C-media
supplemented by ascorbic acid (final concentration 50 mg/ml,
Sigma).
Patients and nerve biopsies
Sural nerve samples from 24 patients undergoing nerve biopsy
for diagnostic reasons were included in the study. Patient’s
characteristics are reported in Table 1. Patients were classified as
regenerating or non-regenerating on the basis of their histological
characteristics at the time of the diagnosis of axonal neuropathy as
described [5]. In brief, we considered regenerating nerves those
with abundant signs of regeneration (Index of regenerating axons
was calculated as the number of regenerating clusters per mm
2 of
sural nerve as follow: 0,40 clusters, 1=41–100, 2=101–200,
3.201). Severity of the neuropathy was assigned counting large/
medium-sized (5–12 mm) myelinated axons in 6–8 representative
areas of sural nerve (0.22–0.28 mm
2); each sural nerve was
classified accordingly to the mean number of large/medium-sized
myelinated axons per mm
2 as follow: very severe ,200 axons,
severe=201–500, moderate=501–1400, mild .1401. The neu-
ropathy was diagnosed by the presence of distal sensory
disturbances with progressive weakness at four limbs, reduced/
absent deep tendon reflexes and neurophysiology showing
reduction of motor/sensory nerve action potentials with variable
slowing of motor/sensory nerve conduction velocities. Patients
underwent routine laboratory tests including screening for
disimmune/inflammatory disorders, liver and kidney function,
glucose intolerance, muscle enzymes, and cerebrospinal fluid
examination. Two independent physicians performed clinical and
histopathological evaluations blindly.
In situ zymography
We determined the activation of the uPA/plasminogen system
in frozen sections by in situ caseinolytic zymography using the
EnzChekH protease green fluorescence assay kit (Invitrogen),
following the protocol previously described [16]. This assay is
based on the release of fluorescent BODIPY FLH-labeled peptides
by plasmin-dependent caseinolysis. Sural nerve sections were
incubated with BODIPY-FLH casein solution (10 mg/ml in Tris-
HCl; Molecular Probes) for 3 h at 37uC. Caseinolytic activity in
nerve sections generated fluorescein peptides that are viewed at
confocal microscopy. To test specificity for uPA, sections were pre-
incubated with a serine protease inhibitor such as 0.5 mM tPA-
STOP (American Diagnostica) or amiloride (0.1 mM; Sigma) at
37uC for 1 h. Semiquantitative analysis of fluorescence staining
was measured by ImageJ (NIH) on images of 0.22–0.26 mm
2 of
sural nerve endoneurium viewed using confocal microscope (Leica
SP5). For grading, we measured the mean gray value correspond-
ing to the sum of the gray value of all pixels in the selected area
divided by the number of pixels, defined as follows: 0 if mean ,1,
0.5 if=2–10, 1 if=11–20, 2 if=21–40, 3 if .41.
SDS-PAGE Zymography
The uPA and tPA activity was evaluated in cell homogenate and
conditioned (C- medium, serum free) media from DRG neuron-
Schwann cell cocultures grown for 5, 10, 15 and 20 days with (or
without) ascorbic acid (50 mg/ml), or sciatic nerve homogenate
from 3 Wt and 3 uPAR2/2 mice. Conditioned medium from
Fibrinolysis and Nerve Repair
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incubation and centrifuged at 14,000 rpm for 5 min to remove
detached cells and debris. Proteins in the medium were
precipitated by the acetone/trichloroacetic acid procedure and
were resuspended in lysis buffer (0.1M Tris-HCl pH 8.0, 0.2%
Triton-X100). Cell monolayers were washed twice with ice-cold
PBS and lysed on the tissue culture dish by addition of ice-cold
lysis buffer. Frozen sciatic nerves dissected from uPAR2/2 and
wild type littermates were pulverized, sonicated in lysis buffer
(0,1M Tris-HCl pH 8,0, 1% Triton-X100, 150 mM NaCl), boiled
for 5 minutes, and spun at 14,000 rpm for 5 min at room
temperature to eliminate insoluble material. Proteins precipitated
from media, cells and nerve homogenate were normalized for
protein concentration using Bio-Rad Bradford kit. Forty micro-
grams of Schwann cell/neuron coculture homogenate, or proteins
precipitated from medium, or 25 mg of nerve extract were
separated on non-reducing SDS/PAGE (10%), after the gels were
washed in 2.5% Triton X100 for 45 minutes and subsequently
placed in contact with a casein gel containing 2% non-fat dry milk,
0.01M Tris-HCl, 1.25% agarose, and plasminogen (6.25 ng/ml;
Roche), at 37uC. After 16 hours, proteolytic activity areas appear
as clear bands on casein gel. The polyacrylamyde gel containing
nerve homogenate was stained in 0.125% (w/v) coomassie brilliant
blue (G-250 Bio-Rad) in 34% methanol, 17% ammonium
sulphate, 3,57% phosphoric acid and destained in 1% acetic acid
solution as loading control and were analyzed by densitometry. As
positive controls, human uPA (0.04 mM, bands 33 and 54 kDa)
and rtPA (ActilyseH 0.01 mM, band 65 kDa) were used.
Statistical analyses
Statistical analyses were evaluated by two tail Student’s t test.
Results
uPAR2/2 mice show normal peripheral nerve
development and function
We assessed whether uPAR loss affects nerve function and
structure. Neurophysiological analysis of uPAR2/2 mice showed
Table 1. Characterization of human nerve biopsies and evaluation of fibrinolytic activity.
Pt. Age/Sex Disease
Severity of the
neuropathy duration Ax Reg
Fibrinolytic
activity FG VN FN
regenerating patients
1* 55/F polyarteritis nodosa moderate 36 m 3 2 0.5 0 2
2* 76/F Wegener granulomatosis moderate 40 m 4 3 0 0.5 2
3* 62/M UCTD mild 24 m 3 2 0 0 2
4* 69/F HCV mix cryoglobulinemia moderate 24 m 3 3 0.5 0 3
5 72/F Chr infl ax neurop moderate 5 y 2 2 0.5 0.5 2
6* 62/M Chr infl ax neurop mild 24 m 3 2 0 0 1
7* 38/M Chr infl ax neurop moderate 24 m 3 3 0 0 0.5
8 40/M CIDP mild 2 y 1 2 1 1 2
9 48/M CIDP mild 3 m 2 3 1 0,5 2
10 44/M CIDP moderate 12 m 1 2 1 0,5 2
11* 73/M idiopathic axonal np moderate 48 m 2 3 0.5 0 2
12* 66/F CMT2 mild 24 m 2 2 0 0 1
13 56/F CMT2 moderate 25 y 1 2 1 0,5 1
average (+SEM) 2.3 (0.06) 2.4 (0.05) 0.4 (0.05) 0.2 (0.05) 1.8 (0.05)
non regenerating patients
14* 60/M polyarteritis nodosa severe 48 m 0 0,5 0,5 1 1
15* 58/M Wegener granulomatosis very severe 18 m 0 0,5 2 0 3
16* 26/F Wegener granulomatosis mild 6 m 0 0,5 2 2 1
17 51/M Wegener granulomatosis moderate 4 m 0 1 3 2 1
18* 24M Chr infl ax neurop moderate 4 m 0 0,5 3 3 1
19 69/F CIDP moderate 3 m 0 0,5 2 2 1
20 30/F CIDP very severe 8 y 0 1 3 2 1
21* 65/M amyloidosis very severe 24 m 0 1 2 1 1
22* 65/M idiopathic axonal np moderate 24 m 0 0,5 1 1 1
23 53/F idiophatic axonal np very severe 36M 0 0,5 2 2 1
24* 69/M toxic neuropathy severe 3 m 0 0,5 2 1 1
average (+SEM) 0 0.6 (0.04) 2.1 (0.08) 1.5 (0.08) 1.2 (0.07)
t test (reg vs non-reg) p,0.001 p,0.001 p,0.001 p,0.001 p=0.02
Legend: CIDP: chronic inflammatory demyelinating neuropathy; CMT: Charcot-Marie-Tooth neuropathy; UCTD: undifferentiated connective tissue disease; ax: axonal;
np: neuropathy. FG: fibrin; VN: vitronectin; FN: fibronectin; m: months; y: years.
*patients already described in
5, respectively pt. #3, 6, 7, 8, 11, 12, 14, 17, 19, 20, 39, 41, 27, 30, 43.
doi:10.1371/journal.pone.0032059.t001
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potentials (Figure 1D). Consistently, morphological analysis of
sciatic nerves did not reveal differences in total fiber number
(Wt 184526270 fibers/mm
2 vs uPAR2/2 177506679 fibers/
mm
2), fiber size distribution and myelination (Figure 1A–C and
1E).
As uPAR-uPA complex plays a role in ECM remodeling, we
then investigated the endoneurial ECM composition. By immu-
nohistochemistry we did not observe differences in the expression
of laminins (a2, b1, b2, c1), fibronectin, and collagen IV (data not
shown). Instead, we observed increased deposition of fibrin and
vitronectin in uPAR2/2 mice (Figure 1F–K, and not shown).
Western blot analysis confirmed increased amount of fibrin and
vitronectin in uPAR2/2 mice (Figure 1L). Thus, uPAR is
dispensable for nerve development.
Since in vitro system may unravel defects masked by compen-
satory or redundant molecules during development in vivo,w e
exploited uPAR2/2 Schwann cell-DRG neuron cocultures. As a
preliminary experiment, we evaluated whether fibrinolytic activity
is present and modulated in cocultures. Thus we evaluated tPA
and uPA activity by zymography in organotypic DRG explants
from wild type mice, in which myelination was induced by
ascorbic acid. We found that both tPA and uPA activity are
induced when myelination starts, and that uPA activity increased
proportionally with myelination (Figure 2A). We then evaluated
myelination of uPAR2/2 DRG explants, measured as number of
Figure 1. Histological characteristics of uPAR null nerve. (A–B) semithin sections from sciatic nerve of Wt (A) and uPAR null mouse (B) showing
normal fiber appearance. (C) Similar fiber type distribution in Wt and uPAR null sciatic nerve. (D) Neurophysiology analysis showing similar values of
cMAP and NCV between Wt and uPAR2/2 mice (n. 10 mice per group). (E) g-ratio did not show differences in myelin thickness between Wt and
uPAR2/2 nerves (n. 20000). (F–K) sciatic nerve cryosections of Wt and uPAR null mouse stained for fibrin fibronectin and vitronectin. Fibrin and
vitronectin staining was mildly increased in uPAR null endoneurium (G and K) as compared to Wt (F and J), whereas fibronectin was similarly
expressed (H–I). (L) Western blot analysis of fibrin and fibronectin in Wt and uPAR null sciatic nerve homogenate. Calnexin was used to normalize
loading (fibronectin and vitronectin were loaded on the same gel, hence they have the same calnexin bands). r=densitometric ratio between the
band of interest and calnexin; Wt was always assigned as r=1. Fibrin and vitronectin levels were increased in uPAR null nerves as compared to Wt,
whereas levels of fibronectin were similar. Fg=fibrin; Fn=fibronectin; Vn=vitronectin; Nf=neurofilaments. Bar=15 mm in A and B; 50 mm in F–K.
doi:10.1371/journal.pone.0032059.g001
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between uPAR2/2 and Wt DRG explants seven days after
ascorbic acid treatment (Figure 2B–F).
Overall, although uPA and tPA activity parallels myelination,
suggesting a role in this process, uPAR is dispensable also in vitro
for myelination during development.
uPAR2/2 mice present significant reduction of repair
after damage
As abnormal fibrin and vitronectin deposition affects nerve
regeneration, we evaluated the response to nerve injury in
uPAR2/2 mice.
We performed sciatic crush injury in 12 uPAR2/2 and 12
littermate control mice and analyzed peripheral nerve regenera-
tion in the nerve stump distally to the site of the lesion at 15 and 45
days post crush (dpc). Fifteen dpc, both wild type and uPAR2/2
nerves showed axonal degeneration, invading macrophages and
few regenerating fibers. The number of regenerating fibers was
significantly reduced (34%) in uPAR2/2 nerves (Wt 58506430/
mm
2 vs uPAR2/2 39006250/mm
2; p=0.02), and consistent for
all fiber diameters (Figure 3A–C). Forty-five dpc, when Wt nerves
are usually regenerated, uPAR2/2 nerves still showed a
significant reduced number (22%) of regenerating fibers (Wt
178006889 fibers/mm
2 versus uPAR2/2 140076260 fibers/
mm
2; p=0.05); this was primarily evident for small diameter fibers
(Figure 3D–F). Consistent with defective regeneration, we also
observed that regenerating fibers in uPAR2/2 mice had reduced
myelin thickness, as measured by g-ratio (Figure 3G; n. 26,
p=0.01). Finally, neurophysiological analysis confirmed impaired
regeneration as uPAR2/2 mice displayed a significant reduction
in NCV as compared to Wt mice at 45 dpc (Figure 3H; n. 8,
p=0.001).
Overall our results suggest that nerve repair is impaired in
uPAR2/2 mice. As uPAR has been associated to leukocyte
migration [7,17], especially into the nervous system during
experimental autoimmune encephalomyelitis [18], we evaluated
if impaired nerve repair in uPAR2/2 mice was due to reduced
macrophage recruitment in the nerve. In fact, macrophage activity
is crucial for myelin clearance in damaged nerve to promote
efficient nerve repair [1]. However, staining for macrophages
using anti-Mac1 antibody did not show a reduced number of
macrophages in uPAR2/2 nerves (Figure 3I–J). The number of
macrophages was similar at 15dpc, while significantly increased in
uPAR2/2 mice at 21dpc (p=0.04) and 45dpc (p=0.008;
Figure 3I–K). An increased number of macrophages in
uPAR2/2 nerve would suggest a delay in clearance of nerve
debris, thus in accordance with a delay in nerve regeneration.
uPAR2/2 mice have reduced fibrinolysis
We then assessed whether defect in nerve repair was mediated
by abnormal ECM composition. We focused on fibrin, fibronectin
and vitronectin, which are targets of the fibrinolytic complex. As
expected, we observed increased expression of fibrin, vitronectin
and fibronectin after nerve damage in the endoneurium of both
Figure 2. Fibrinolytic molecules in myelination. (A) Time course zymography of uPA and tPA activity in Wt DRG explant homogenate (as a pool
of at least 8 coverslips) and their conditioned media without ascorbic acid treatment (-) or after 5, 10, 15, 20 days of ascorbic acid (+). Note both tPA
and uPA activity are induced after ascorbic acid in both cell homogenate and media, although uPA activity increases in parallel with myelination. (B–
E) DRG explants from Wt and uPAR null mice stained for neurofilament (green) and MBP (red) 7 days after ascorbic acid. The number of myelinated
segments were similar between Wt and uPAR null explants. Bar=50 mm.
doi:10.1371/journal.pone.0032059.g002
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tently higher in uPAR2/2 mice (Figure 4A–F and Figure 5A;
values are expressed as average of 3 experiments6SEM). At 45
dpc, when nerve should be almost recovered, Wt nerves showed
roughly normal levels of all three ECM molecules, whereas fibrin
and vitronectin levels were still increased in mutant nerves
(Figure 4G–L and Figure 5A), and fibronectin levels markedly
decreased (Figure 5A). Overall these results suggest that normal
remodeling of ECM after damage is impaired in uPAR2/2 mice,
which consistently have higher levels of fibrin and vitronectin.
We therefore evaluated whether uPAR2/2 mice have a
defective function of the fibrinolytic complex. Nerve tissue from
the crush site of 3 Wt and 3 uPAR2/2 mice was obtained at 7
and 15 dpc and from non-injured nerves. tPA and uPA activity
was determined by zymography (the experiment was performed 3
times). In non-injured nerve, uPA and tPA activity was similar
between uPAR2/2 and Wt mice. After nerve damage, uPA and
tPA activity was modulated in Wt nerves, reaching a peak at 7dpc
and decreasing at 15dpc (Figure 5B). In uPAR2/2 mice instead,
uPA activity was only mildly increased and not modulated
(Figure 5B).
These results demonstrate that uPAR2/2 mice have a reduced
uPA activity after nerve damage, which sustains their inability to
degrade fibrin.
Exogenous fibrinolytic treatment ameliorate nerve repair
in uPAR2/2 mice
To verify whether reduced fibrin deposition would improve
nerve repair in uPAR2/2 mice, we performed exogenous
fibrinolysis by treating mice with recombinant (r)tPA (5 mg/ml;
ActilyseH). We first verified that intra-peritoneal administration of
rtPA (roughly 1 mg per mouse) was sufficient to remove fibrin in
the endoneurium of uPAR2/2 crushed sciatic nerves. Five
uPAR2/2 and 5 Wt mice have been treated with rtPA either
other day from 1dpc and the sciatic nerve analyzed at 4dpc.
Fibrin that is highly expressed in the endoneurium of non-treated
mice was reduced in the endoneurium of rtPA treated mice
(Figure 6A–D).
Figure 3. Sciatic nerve regeneration after injury. (A–B, D–E) semithin section and (C, F) fiber type distribution from sciatic nerve of Wt and uPAR
null mice at 15 and 45 dpc. At both 15 and 45 dpc we observed reduced number of regenerating fibers. (G) g-ratio was significantly increased in
uPAR2/2 regenerating fibers at 45 dpc (n. 20000; p=0.01). (H) Neurophysiological analysis showing similar values of cMAP between Wt and uPAR2/2
mice, whereas NCV was significantly reduced in uPAR2/2 mice (n. 8; p=0.001). (I–J) Staining for Mac-1/CD11b (Mac1) in Wt (I) and uPAR null (J) sciatic
nerve 45dpc. (K) Quantification of number of macrophages observed in sciatic nerve 15, 21 and 45dpc; differences were significant at 21 and 45 dpc
(*p=0.04; **p=0.008). Bar=10 mm in A, B, D, E, I and J.
doi:10.1371/journal.pone.0032059.g003
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mice and treated these mice for 3 weeks, 2 times per week from
1dpc, with rtPA (5 mg/100 g). Forty-five dpc, motor nerve
conduction velocities and cMAPs were similar in uPAR null mice
and controls (Figure 6H). Accordingly, both wild type and
uPAR2/2 nerves showed quite complete nerve recovery, and
we did not observe differences in total number of fibers (Wt
1630061082 fibers/mm
2 vs uPAR2/2 1768061090 fibers/
mm
2), fiber type distribution (Figure 6E–G) and myelin thickness
(Figure 6I). Immunohistochemistry for fibrin expression showed
similar pattern in Wt and uPAR2/2 mice (Figure 6J–K).
Human neuropathies show different fibrinolytic complex
activity
Our previous findings indicate that nerve regeneration in
human neuropathies is impaired in the presence of abnormal
accumulation of fibrin and vitronectin in the endoneurium [5]. We
investigated whether the fibrinolytic activity is involved in the
abnormal deposition of fibrin and vitronectin in peripheral nerves
of human neuropathies (Table 1). We analyzed 24 nerve biopsies
from patients affected by peripheral neuropathy that, on
histopathology evaluation, were divided in regenerative (patients
#1–13) and non-regenerative (patients #14–24) neuropathies. On
these nerve samples, we performed in situ zymography and
observed that all the nerves showing higher fibrinolytic activity
belong to the group of regenerating neuropathies (Table 1 and
Figure 7). This result was independent from the diagnosis of the
neuropathy. When an inhibitor of tPA or uPA activity was added
before zymography, the fluorescent activity was reduced or
abolished, confirming the specificity of the result Figure 7A
I–B
I.
Consistently, nerves with signs of regeneration and high
fibrinolytic activity showed significantly lower expression of fibrin
and vitronectin (Table 1). On the contrary, patients with no signs
of regeneration and low fibrinolytic activity showed significantly
higher expression of fibrin and vitronectin (Table 1).
Overall these data suggest that efficient fibrinolytic activity
remodelsthe endoneurialECMinorder to favornerveregeneration.
Discussion
Given the role of the fibrinolytic complex in nerve regeneration,
the molecular characterization of its major components is
Figure 4. Different expression of ECM in uPAR2/2 nerves after damage. Sciatic nerve cryosections from Wt (A, C, E, G, I, K) and uPAR2/2 (B,
D, F, H, J, L) mice stained for fibrin (Fg), fibronectin (Fn) or vitronectin (Vn), and neurofilaments (Nf) at 15 and 45 dpc. Both at 15 and 45 dpc Fibrin
expressions was higher in uPAR2/2 as compared to Wt endoneurium (B versus A, and H versus G). Fibronectin expression was similarly in Wt and
uPAR2/2 mice at both time points (D versus C, and J versus I). Vitronectin expression was higher in uPAR2/2 mice as compared to wt at 15dpc (F
versus E), whereas it was similar at 45 dpc (L and K). Bar=50 mm.
doi:10.1371/journal.pone.0032059.g004
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therapeutical intervention. We therefore investigated the role of
uPAR by loss of function experiments, as its spatial and temporal
expression suggested its involvement in nerve function [9,10]. We
observed that uPAR plays a role in nerve regeneration, as it is
necessary for proper remodeling of the endoneurial ECM.
Proper fibrin remodeling is critical for nerve repair. Soon after
nerve damage, an immature ECM composed by fibrin clot is
instrumental for tissue reorganization and successful regeneration
[5,19]. However, to proceed towards regeneration, the fibrin clot
has to be removed to form ‘‘mature’’ ECM enriched in fibronectin
[5,20]. Mice devoid of fibrin show accelerated nerve regeneration
after injury [19,21], suggesting that fibrin is a negative regulator of
nerve repair. Consistently, in uPAR2/2 mice we observed the
inverse result. Loss of uPAR causes excessive fibrin and vitronectin
deposition due to impaired uPA activity, which results in reduced
nerve repair. Consistently, when we forced fibrinolysis by
exogenous administration, we reduced endoneurial fibrin deposi-
tion and ameliorated nerve repair in uPAR2/2 mice. Hence, our
results suggest that uPAR is necessary for proper uPA fibrinolytic
activity and repair in peripheral nerve.
Leukocytes, including macrophages, express uPAR [7], which
mediate adhesion and migration to sites of inflammation through
interaction with ECM molecules, mainly vitronectin [17]. In
uPAR2/2 mice, this lack of interaction is responsible for delayed
and less acute spinal cord inflammation in experimental allergic
encephalomyelitis [18]. In the peripheral nerve, macrophage
recruitment and infiltration at site of nerve injury is fundamental
for the removal of myelin and axonal debris, and to promote
efficient regeneration. However, conversely to what is described in
the central nervous system, loss of uPAR does not reduce
macrophage infiltration in the injured nerves. A different
repertoire of adhesive receptors is likely involved in the
macrophage recruitment into the peripheral nerve, which is
alternative to uPAR-vitronectin [22,23].
This article and others [6,10,19,21,24,25] clearly show that the
fibrinolytic complex is involved in nerve regeneration in animal
models. We already described that remodeling of ECM, and
particularly the clearance of fibrin in the endoneurium, is
fundamental for nerve regeneration in human neuropathies [5].
Now we show for the first time that the activity of the fibrinolytic
complex is different in nerve biopsies of human neuropathies,
Figure 5. Impaired uPA activity and fibrin clearance in uPAR2/2 nerves after damage. (A) western blot analysis of fibrin and fibronectin in
Wt and uPAR null sciatic nerve homogenate at 15, 21 and 45 dpc. Calnexin was used to normalize loading. Quantification of western blot is reported
as an average of 3 independent experiments, and represented as ratio fibrin/calnexin, vitronectin/calnexin and fibronectin/calnexin, assigning Wt
0dpc as 16SEM). At each time point uPAR null homogenate showed increased levels of fibrin and vitronectin as compared to Wt, whereas fibronectin
levels were higher at 15 and 21 dpc, but lower at 45 dpc. (B) Zymography of sciatic nerve homogenate from Wt and uPAR null mice measuring tPA
and uPA activity 0, 7 and 15dpc. Bands were stained with Coomassie blue as loading control. Quantification of zymography is reported as an average
of 3 independent experiments, and represented as ratio uPA/coomassie blue and tPA/coomassie blue, assigning Wt 0dpc as 16SEM. Note the
reduced increase of uPA in uPAR null homogenate as compared to Wt 7 and 15dpc, whereas there are no differences in the tPA activity between
mutant and Wt mice. Fg=fibrin; Fn=fibronectin; Vn=vitronectin; Cln=calnexin.
doi:10.1371/journal.pone.0032059.g005
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vitronectin is low, and vice-versa. We showed that neuropathies
with defective regeneration, and worse clinical outcome, had
reduced fibrinolytic activity. On the contrary, neuropathies with
active signs of regeneration, and better clinical outcome, displayed
high fibrinolytic activity. These results are in agreement with the
Figure 6. Exogenous recombinant tPA rescues abnormal myelination in uPAR null nerves after injury. (A–D) Sciatic nerve cryosections
from Wt and uPAR null mice stained for fibrin 4 dpc without or after exogenous treatment with recombinant tPA (5 mg/100 g). After treatment fibrin
staining is mostly abolished (compare C and A). (E–F) semithin sections from sciatic nerve 45 dpc of Wt and uPAR null mice after treatment with
recombinant tPA (5 mg/100 g , 2 times per week for 3 weeks), and (G) fiber type distribution. Number and fiber type distribution was similar in the
two groups. (H) Neurophysiology analysis showing similar values of cMAP and NCV between Wt and uPAR2/2 mice treated with rtPA at 45 dpc. (I) g-
ratio did not show differences in myelin thickness between Wt and uPAR2/2 nerves (n. 15000). (J–K) immunofluorescence staining for fibrin in sciatic
nerves at 45 dpc from mice treated with rtPA, showing low expression of fibrin. Fg=fibrin; Nf=neurofilaments. Bar=50 mm in A–D and J–K; 20 mmi n
E–F.
doi:10.1371/journal.pone.0032059.g006
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after damage and facilitate Schwann cell-axon interaction.
Interestingly, our results were independent from the pathogenetic
mechanism of the neuropathy, suggesting that this is a general
mechanism associated to nerve regeneration. We are tempting to
speculate that exogenous fibrinolysis might constitute an associa-
tive therapy to ameliorate pathological and clinical outcome of a
subset of peripheral neuropathies. On the other hand, drug
(Actilyse H) and dosage we used in this study would not be
sufficiently safe to be translated in humans. The high risk for
haemorrhages as side effect, makes Actilyse inappropriate for not
life threatening disorders such as peripheral neuropathy. More-
over, although in our small case series we did not observe
haemorrages in treated mice, careful autopsy was not performed.
This important side effect should be investigated in a larger series
of mice before envisage any translation in human to treat
neuropathies.
In conclusion, our results propose uPAR as a molecule involved
in the fibrinolityc activity in peripheral nerve repair. Moreover,
our findings sustain that the fibrinolytic complex plays a role in
nerve repair in human neuropathies, suggesting that enhanced
fibrinolysis may ameliorate the pathology and the outcome of
peripheral neuropathies. Further studies with drugs with minor
side effects and in selected animal models of human neuropathies
would be necessary to address this hypothesis.
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